Search

Displaying results 291 - 300 of 4297 in total
  1. Drug

    Itraconazole

    go.drugbank.com/drugs/DB01167
    ApprovedInvestigational

    [L50051] Itraconazole was first approved in the US in 1992 [L50056] and is available orally. … While the intravenous formulation of the drug was formerly available, it was discontinued in the US in 2007.[A263232]

  2. Drug

    Pancrelipase amylase

    go.drugbank.com/drugs/DB11065
    ApprovedInvestigational

    [L2509] The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. … [L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

  3. Drug

    Piperaquine

    go.drugbank.com/drugs/DB13941
    ApprovedInvestigational

    Its use declined in the 1980's as piperaquine resistant strains of *Plasmodium falciparum* appeared and artemisinin derivatives became available. … Eurartesim was first authorized for market by the European Medicines Agency in October 2011.

  4. Drug

    Glucosamine

    go.drugbank.com/drugs/DB01296
    Approved

    [A231894,A232289] It is currently not approved as a prescription product by the FDA, but is widely available over the counter. … Osteoarthritis (OA) is a progressive and degenerative joint disease marked by loss of cartilage, bone changes, and synovial membrane inflammation.

  5. Drug

    Pidolic acid

    go.drugbank.com/drugs/DB03088
    ApprovedInvestigational

    Pidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics … There are currently little to no medicines available that are clinically approved or marketed for employing pidolic acid as an active ingredient for any particular formal indication.

  6. Drug

    Triazolam

    go.drugbank.com/drugs/DB00897
    ApprovedInvestigational

    This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.

  7. Drug

    Nitroprusside

    go.drugbank.com/drugs/DB00325
    ApprovedInvestigational

    Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing...

  8. Drug

    Aluminum sulfate

    go.drugbank.com/drugs/DB11239
    Approved

    By overcoming the body barriers, Al may infiltrate into the blood and lead to toxic effects in liver, bone and the central nervous system [L2145].

  9. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical … In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.

  10. Drug

    Acellular nerve allograft

    go.drugbank.com/drugs/DB30293
    ApprovedInvestigational

    Our team is working on the full update, which will be available soon. [L54673,L54668] … Approved by the FDA under a Biologics License Application (BLA) as an acellular nerve scaffold for the treatment of adult and pediatric patients (aged ≥1 month) with sensory, mixed, and motor peripheral